Japan Plans New Regenerative-Medicine Rules To Free Local Makers
This article was originally published in PharmAsia News
Executive Summary
Japan regulators are making plans to allow clinical research data from medical institutions to be cited as proof of efficacy in applications for approval of regenerative medical products, including drugs and medical devices.